Circulating tumor cells and their role in prostate cancer  

作　　者：Moritz Maas Miriam Hegemann Steffen Rausch Jens Bedke Arnulf Stenzl Tilman Todenhofer 

机构地区：[1]Department of Urology,University Hospital Tuebingen,Hoppe-Seyler-Strabe 3,Tuebingen 72076,Germany.

出　　处：《Asian Journal of Andrology》2019年第1期24-31,共8页亚洲男性学杂志（英文版）

摘　　要：Circulating tumor cells (CTC)have become an important biomarker in patients with advanced prostate cancer.CTC count has been demonstrated to be a prognostic factor for overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC). In localized prostate cancer,a clear correlation between CTC counts and clinicopathological risk parameters and outcome has not been observed.Currently,the focus of research is shifting from CTC enumeration towards molecular characterization of CTC leading to the discovery of markers predicting treatment response.The role of androgen receptor splice variants expressed by CTC as markers of resistance to abiraterone and enzalutamide has been assessed by various studies.The identification of CTC markers predicting treatment response represents a key step to guide the selection of treatment (e.g.,abiraterone/enzalutamide vs taxanes), particularly in patients with mCRPC.As an alternative to CTC,the analysis of circulating tumor DNA has been shown to enable a noninvasive disease characterization having high potential to promote precision oncology.

关 键 词：AR-V7 biomarker CELL-FREE DNA cfDNA CIRCULATING tumor cells CTDNA liquid BIOPSY PROSTATE cancer 

分 类 号：R[医药卫生]